Small Molecule for Drug Overdose and Drug Toxicity is under clinical development by ResQ Pharma and currently in Phase III for Drug Toxicity. According to GlobalData, Phase III drugs for Drug Toxicity have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Small Molecule for Drug Overdose and Drug Toxicity’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small Molecule for Drug Overdose and Drug Toxicity overview
Lipid rescue therapy (LRT) is under development for the treatment of local anesthetic systemic toxicity (LAST) and for the toxicity, poisoning, overdose of non-opioid drugs (NODO). LRT contains lipid emulsions administered as an intravenous infusion.
ResQ Pharma overview
ResQ Pharma is a research and development company. The company is headquartered in Chicago, Illinois, the US
For a complete picture of Small Molecule for Drug Overdose and Drug Toxicity’s drug-specific PTSR and LoA scores, buy the report here.